Cargando…
Ecallantide for the Treatment of Hereditary Angiodema in Adults
Hereditary angioedema (HAE) is a clinical disorder characterized by a deficiency of C1 esterase inhibitor (C1-INH). HAE has traditionally been divided into two subtypes. Unique among the inherited deficiencies of the complement system, HAE Types I and II are inherited as an autosomal dominant disord...
Autores principales: | Lunn, Michael, Banta, Erin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115639/ https://www.ncbi.nlm.nih.gov/pubmed/21695090 http://dx.doi.org/10.4137/CMC.S4434 |
Ejemplares similares
-
Management of acute attacks of hereditary angioedema: role of ecallantide
por: Duffey, Hannah, et al.
Publicado: (2015) -
Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency
por: Farkas, Henriette, et al.
Publicado: (2011) -
87 Treatment of Idiopathic Nonhistaminergic Angiodema with Icatibant
por: Lleonart, Ramon, et al.
Publicado: (2012) -
Allergic diseases of the skin and drug allergies – 2035. Allergen control in management of chronic urticaria/angiodema (CUA) in Kenya, East Africa
por: Bowry, Tula, et al.
Publicado: (2013) -
Cinryze(™) as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety
por: Lunn, Michael, et al.
Publicado: (2010)